Specialties

weekly news, by specialty

A weekly roundup of innovation in 25 medical specialties and four therapy specialties: new technology, AI tools, devices, FDA decisions and new ways of delivering care, published every Sunday. Every item links to its sources.

Latest roundups:

Your specialty

  • Family medicine

    Team care with single pills lowers blood pressure in CATCH; GLP-1 drugs get optic neuropathy warning; PAHO reportedly revokes measles status

    Nov. 8 to 14, 2026

  • Internal medicine

    FDA approves first factor XIa inhibitor after stroke; smartwatch AI flags weak pumping; GLP-1 drugs get optic neuropathy warning

    Nov. 8 to 14, 2026

  • Pediatrics

    Reports say PAHO revoked U.S. measles elimination status; school accommodations fail in ADHD trial; Alaris kit correction made Class I

    Nov. 8 to 14, 2026

  • Anesthesiology

    Holding ACE inhibitors or ARBs before surgery cuts hypotension; FDA alerts on Intersurgical breathing tubes and Arrow guidewires

    Nov. 8 to 14, 2026

  • Emergency medicine

    Statewide CPR and EMS program does not raise cardiac arrest survival; AI model predicts ROSC from end-tidal CO2; breathing tubes recalled

    Nov. 8 to 14, 2026

  • Hospital medicine

    Deprescribing stewardship gives small gain in older inpatients; FDA approves asundexian after stroke; Arrow guidewires and Alaris sets flagged

    Nov. 8 to 14, 2026

  • Pulmonary and critical care

    Orforglipron cuts sleep apnea events in ATTAIN-OSA; FDA flags breathing tube connector risk; Alaris kit recall is Class I

    Nov. 8 to 14, 2026

  • Cardiology

    Left bundle branch pacing cuts events in OptimPacing; AI echo drafts match human reports; Impella controller recall is Class I

    Nov. 8 to 14, 2026

  • Dermatology

    Oral minoxidil VDPHL01 keeps hair gains at 12 months, company says; morphea and systemic sclerosis tied to higher cancer incidence

    Nov. 8 to 14, 2026

  • Endocrinology

    FDA adds optic neuropathy warning to all GLP-1 drugs; Tandem Mobi cleared to run tubeless; survodutide meets cardiovascular safety bar

    Nov. 8 to 14, 2026

  • Gastroenterology

    Elebsiran-tobevibart meets phase 3 hepatitis delta goal; efinopegdutide resolves MASH in phase 2b; dabigatran recanalizes portal vein thrombosis

    Nov. 8 to 14, 2026

  • Infectious disease

    Reports say PAHO revoked U.S. measles elimination status; elebsiran-tobevibart meets hepatitis delta goal; doxycycline tied to pregnancy loss

    Nov. 8 to 14, 2026

  • Nephrology

    FDA approves obinutuzumab as first drug for primary membranous nephropathy; dapagliflozin improves eGFR slope after heart transplant

    Nov. 8 to 14, 2026

  • Neurology

    FDA approves first factor XIa inhibitor after stroke; MRI brain-age model predicts decline; review finds bypass triage evidence insufficient

    Nov. 8 to 14, 2026

  • Oncology

    FDA approves durvalumab with enfortumab vedotin for bladder cancer; ACS backs regular PSA screening; camrelizumab lifts event-free survival

    Nov. 8 to 14, 2026

  • Psychiatry

    Compass files psilocybin application for resistant depression; FDA reportedly shelves priority voucher program; lumateperone meets mania end point

    Nov. 8 to 14, 2026

  • General surgery

    Oral antibiotics are noninferior after appendectomy for complicated appendicitis; digital follow-up tied to fewer readmissions

    Nov. 8 to 14, 2026

  • Neurosurgery

    FDA rejects Novocure's Optune Mya for lung cancer brain metastases; Synchron pauses Stentrode enrollment; MRI model predicts meningioma grade

    Nov. 8 to 14, 2026

  • Obstetrics and gynecology

    Early-pregnancy doxycycline tied to higher pregnancy loss risk; mobile coaching fails to cut postpartum BMI; most fibroid patients avoid retreatment

    Nov. 8 to 14, 2026

  • Ophthalmology

    FDA adds NAION warning to all GLP-1 drugs; optic neuritis often heralds CNS inflammatory disease

    Nov. 8 to 14, 2026

  • Orthopedic surgery

    Routine radiographs after joint replacement rarely change care; newer AI model hallucinates less; FDA approves pimicotinib for TGCT

    Nov. 8 to 14, 2026

  • Otolaryngology

    Oral orforglipron cuts sleep apnea events in ATTAIN-OSA; preoperative grading system stratifies sinus surgery outcomes

    Nov. 8 to 14, 2026

  • Urology

    FDA approves perioperative durvalumab plus enfortumab vedotin for bladder cancer; ACS backs regular PSA screening; bladder robot gets De Novo nod

    Nov. 8 to 14, 2026

  • Pathology

    FDA finalizes validation guidance for emergency pathogen tests; first BD OneFlow lymphoma tests cleared; NKF report favors urinary albumin

    Nov. 8 to 14, 2026

  • Radiology

    SNMMI-led criteria back FET PET for glioma; Bracco announces FDA-cleared aneurysm AI; Cu-64 PSMA agent gets breakthrough designation

    Nov. 8 to 14, 2026

  • Physical therapy

    Intensive bimanual and leg therapy lifts gross motor scores in preschoolers with cerebral palsy; early brain stimulation curbs poststroke spasticity

    Nov. 8 to 14, 2026

  • Occupational therapy

    Carpal tunnel network meta-analysis ranks shockwave first at mid-term; HABIT-ILE lifts COPM scores in preschoolers with cerebral palsy

    Nov. 8 to 14, 2026

  • Speech-language pathology

    Dysphagia-optimized radiotherapy lowers late swallowing problems after oral cancer surgery; journal retracts complex syntax test study

    Nov. 8 to 14, 2026

  • Psychology and social work

    Chatbots with intensive human support show an edge in very low-certainty meta-analysis; digital insomnia tools no substitute for in-person therapy

    Nov. 8 to 14, 2026

Primary care

  • Family medicine

    Team care with single pills lowers blood pressure in CATCH; GLP-1 drugs get optic neuropathy warning; PAHO reportedly revokes measles status

    Nov. 8 to 14, 2026

  • Internal medicine

    FDA approves first factor XIa inhibitor after stroke; smartwatch AI flags weak pumping; GLP-1 drugs get optic neuropathy warning

    Nov. 8 to 14, 2026

  • Pediatrics

    Reports say PAHO revoked U.S. measles elimination status; school accommodations fail in ADHD trial; Alaris kit correction made Class I

    Nov. 8 to 14, 2026

Hospital and acute care

  • Anesthesiology

    Holding ACE inhibitors or ARBs before surgery cuts hypotension; FDA alerts on Intersurgical breathing tubes and Arrow guidewires

    Nov. 8 to 14, 2026

  • Emergency medicine

    Statewide CPR and EMS program does not raise cardiac arrest survival; AI model predicts ROSC from end-tidal CO2; breathing tubes recalled

    Nov. 8 to 14, 2026

  • Hospital medicine

    Deprescribing stewardship gives small gain in older inpatients; FDA approves asundexian after stroke; Arrow guidewires and Alaris sets flagged

    Nov. 8 to 14, 2026

  • Pulmonary and critical care

    Orforglipron cuts sleep apnea events in ATTAIN-OSA; FDA flags breathing tube connector risk; Alaris kit recall is Class I

    Nov. 8 to 14, 2026

Medical specialties

  • Cardiology

    Left bundle branch pacing cuts events in OptimPacing; AI echo drafts match human reports; Impella controller recall is Class I

    Nov. 8 to 14, 2026

  • Dermatology

    Oral minoxidil VDPHL01 keeps hair gains at 12 months, company says; morphea and systemic sclerosis tied to higher cancer incidence

    Nov. 8 to 14, 2026

  • Endocrinology

    FDA adds optic neuropathy warning to all GLP-1 drugs; Tandem Mobi cleared to run tubeless; survodutide meets cardiovascular safety bar

    Nov. 8 to 14, 2026

  • Gastroenterology

    Elebsiran-tobevibart meets phase 3 hepatitis delta goal; efinopegdutide resolves MASH in phase 2b; dabigatran recanalizes portal vein thrombosis

    Nov. 8 to 14, 2026

  • Infectious disease

    Reports say PAHO revoked U.S. measles elimination status; elebsiran-tobevibart meets hepatitis delta goal; doxycycline tied to pregnancy loss

    Nov. 8 to 14, 2026

  • Nephrology

    FDA approves obinutuzumab as first drug for primary membranous nephropathy; dapagliflozin improves eGFR slope after heart transplant

    Nov. 8 to 14, 2026

  • Neurology

    FDA approves first factor XIa inhibitor after stroke; MRI brain-age model predicts decline; review finds bypass triage evidence insufficient

    Nov. 8 to 14, 2026

  • Oncology

    FDA approves durvalumab with enfortumab vedotin for bladder cancer; ACS backs regular PSA screening; camrelizumab lifts event-free survival

    Nov. 8 to 14, 2026

  • Psychiatry

    Compass files psilocybin application for resistant depression; FDA reportedly shelves priority voucher program; lumateperone meets mania end point

    Nov. 8 to 14, 2026

Surgical specialties

  • General surgery

    Oral antibiotics are noninferior after appendectomy for complicated appendicitis; digital follow-up tied to fewer readmissions

    Nov. 8 to 14, 2026

  • Neurosurgery

    FDA rejects Novocure's Optune Mya for lung cancer brain metastases; Synchron pauses Stentrode enrollment; MRI model predicts meningioma grade

    Nov. 8 to 14, 2026

  • Obstetrics and gynecology

    Early-pregnancy doxycycline tied to higher pregnancy loss risk; mobile coaching fails to cut postpartum BMI; most fibroid patients avoid retreatment

    Nov. 8 to 14, 2026

  • Ophthalmology

    FDA adds NAION warning to all GLP-1 drugs; optic neuritis often heralds CNS inflammatory disease

    Nov. 8 to 14, 2026

  • Orthopedic surgery

    Routine radiographs after joint replacement rarely change care; newer AI model hallucinates less; FDA approves pimicotinib for TGCT

    Nov. 8 to 14, 2026

  • Otolaryngology

    Oral orforglipron cuts sleep apnea events in ATTAIN-OSA; preoperative grading system stratifies sinus surgery outcomes

    Nov. 8 to 14, 2026

  • Urology

    FDA approves perioperative durvalumab plus enfortumab vedotin for bladder cancer; ACS backs regular PSA screening; bladder robot gets De Novo nod

    Nov. 8 to 14, 2026

Diagnostic specialties

  • Pathology

    FDA finalizes validation guidance for emergency pathogen tests; first BD OneFlow lymphoma tests cleared; NKF report favors urinary albumin

    Nov. 8 to 14, 2026

  • Radiology

    SNMMI-led criteria back FET PET for glioma; Bracco announces FDA-cleared aneurysm AI; Cu-64 PSMA agent gets breakthrough designation

    Nov. 8 to 14, 2026

Therapy specialties

  • Physical therapy

    Intensive bimanual and leg therapy lifts gross motor scores in preschoolers with cerebral palsy; early brain stimulation curbs poststroke spasticity

    Nov. 8 to 14, 2026

  • Occupational therapy

    Carpal tunnel network meta-analysis ranks shockwave first at mid-term; HABIT-ILE lifts COPM scores in preschoolers with cerebral palsy

    Nov. 8 to 14, 2026

  • Speech-language pathology

    Dysphagia-optimized radiotherapy lowers late swallowing problems after oral cancer surgery; journal retracts complex syntax test study

    Nov. 8 to 14, 2026

  • Psychology and social work

    Chatbots with intensive human support show an edge in very low-certainty meta-analysis; digital insomnia tools no substitute for in-person therapy

    Nov. 8 to 14, 2026

About these roundups

Each roundup covers innovation in the specialty announced or published in the seven days before it comes out, Sunday through Saturday: new technology and devices, artificial intelligence tools and the studies that test them, decisions by the Food and Drug Administration on new technology, and new ways of delivering care. Routine clinical news (a new drug, a treatment trial, a guideline or a shortage) is left out unless a new technology or a new care model is its subject. A roundup runs five to seven items in a busy week and fewer in a quiet one. Each specialty's roundup is also read aloud as a weekly podcast.

Items come from primary sources where possible (the journal article, the agency notice, the society statement), with news coverage linked as a second source, and every roundup is checked against its sources before it is published. Company announcements and results that have not been peer reviewed are identified as such. The roundups are news, not medical advice.